International Network of Special Immunization Services

Protecting the health of populations and building trust in vaccine safety during the COVID-19 pandemic and beyond through in-depth evaluation of adverse events following immunization (AEFIs) to understand their causes and how to prevent them.

 

INSIS brings together specialist clinicians, international experts in vaccine safety, systems biology, and genomics to characterize the clinical spectrum, risk factors, and underlying mechanisms of adverse events following COVID-19 immunization such as:

  • Myocarditis

  • Pericarditis

  • Thrombosis with Thrombocytopenia Syndrome (TTS)

 
Vaccines are very safe. However, rare serious AEFIs that occur in fewer than 1 in 10,000 vaccinations may not be detected until vaccines are rolled out to the general population. INSIS represents an international effort to understand, respond to, and prevent these very rare events. 

This collaborative effort has the potential to advance the science and delivery of safe vaccines worldwide in a manner that no one country could do alone.
 
 

A Truly Global Network for Vaccine Safety

INSIS seeks to build capacity for AEFI investigation in both high-income and low-middle-income countries. Through partnerships with local specialists, public health agencies, and research networks, INSIS aims to increase vaccine confidence by informing regulatory and policy decision-making regarding the benefit-risk assessment of vaccines.